Chinese Researchers Develop New Hydrogel for Type 1 Diabetes Treatment
The rate of Type 1 Diabetes has been quickly increasing in recent years. An alarming trend is that people are getting this disease at a younger age. The diabetes needs to purchase drugs regularly in order to stabilize the illness and strictly control the sugar intake. The cost of drugs in America is expensive. Because of this, international students are required to purchase international student insurance (aka 留学生 保险) and F-2 insurance (aka f2保险) for their dependents or J1/J2 insurance (aka j1 j2 保险) for visiting scholars.
In fact, not only students who need drugs, but all international students are required to purchase health insurance during their stay in America. After they graduate, purchasing a health insurance for OPT (aka opt期间保险) or H-1B insurance (aka h1b 保险) is highly recommended just in case of emergent condition. Some students choose to waive American university insurance (aka waive 美国大学保险). It is a good choice since some marketplace health insurance plans offer equivalent benefits included in college insurance plans at a lower price.
Diabetes drugs balance the insulin level. Recently, Chinese researchers have achieved a breakthrough in developing a new type of hydrogel material for type 1 diabetes mellitus (T1DM) treatment, according to a research team from Tianjin University. Islets can be coated with the new hydrogel which can serve as an excellent immunoprotective material for islet transplantation therapy, said the research group led by Zhang Lei, professor of the university’s chemical engineering and technology school.
T1DM is a chronic disease affecting around 30 million people worldwide. Transplantation of encapsulated islets is a promising treatment for the patients. According to Zhang, the encapsulated islets can maintain their glucose-responsive and insulin-producing functions. The hydrogel can effectively evade in vivo immune recognition after being implanted in the experimental mice with T1DM.
In the experiment, 100 percent of the mice rapidly recovered to a stable blood sugar level within 2 days and remained at least 150 days without any immunosuppression treatment, in contrast with the traditional hydrogel that required 5 to 7 days to achieve blood sugar control, maintaining only for around 20 days. Zhang said the new type of hydrogel has significant advantages in speed and stability of blood sugar control. “It’s easy to produce it with low cost and has a great potential to be widely used in medical and health field concerning cell treatment and tissue engineering.” The research has been published in the newest edition of Advanced Functional Materials and applied for the utility patent in China.